Gayle S. Jameson
YOU?
Author Swipe
View article: Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer
Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer Open
NCT03410030.
View article: Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma
Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma Open
View article: A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer
A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer Open
SUMMARY Background In this Phase II randomized clinical trial, we evaluated a medically supervised ketogenic diet (MSKD) compared to a usual diet (non-MSKD) when combined with the triplet chemotherapy regimen of gemcitabine, nab-paclitaxel…
View article: Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma
Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma Open
Background: Pancreatic ductal adenocarcinoma (PC) is an aggressive form of cancer treated with chemotherapy regimens such as leucovorin, 5-fluorouracil (5-FU), irinotecan, oxaliplatin (FOLFIRINOX), and gemcitabine plus albumin-bound paclit…
View article: Skin microbiome differences in pancreatic adenocarcinoma, other cancers, and healthy controls: a pilot study
Skin microbiome differences in pancreatic adenocarcinoma, other cancers, and healthy controls: a pilot study Open
Introduction Many studies have reported the importance of the human microbiome in relationship to the overall health of its host. While recent studies have explored the microbiome’s role in various types of cancer compared to healthy patie…
View article: Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction Open
Lessons learned Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life. Background Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with the tumor micro…
View article: Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer
Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer Open
Background Chemotherapy-induced peripheral neuropathy (CIPN), a common problem, can impair function and quality of life in patients, potentially limiting chemotherapy and adversely affecting outcomes. Methods This trial compared investigat…
View article: Phase <scp>II</scp> clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (<scp>NABPLAGEM</scp>) in patients with untreated advanced pancreatic cancer
Phase <span>II</span> clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (<span>NABPLAGEM</span>) in patients with untreated advanced pancreatic cancer Open
Background A previous phase IB/II study of nab‐paclitaxel + cisplatin + gemcitabine (NABPLAGEM) in 25 patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrated favorable results. This phase II study…
View article: Figure S5 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S5 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Correlation between the average irinotecan concentration of the biopsied lesion of that patient and the patient's time on treatment. Biopsy samples were obtained 72 hours after nal-IRI infusion. Time on treatment is measured from the date …
View article: Figure S6 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S6 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
ROC analysis of FMX lesion response. Receiver operating characteristics for lesion classification according to best lesion size reduction, either as overall lesion shrinkage or partial response criteria, had an AUC {greater than or equal t…
View article: Figure S2 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S2 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Example patient (patient 009) with widespread hepatic metastasis who demonstrated a treatment response following therapy. (A) Selected axial images from FMX-MRI acquired from the FSPGR Fat-Sat breath-hold images (TE = 13.2 milliseconds). T…
View article: Figure S4 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S4 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Additional Prussian blue and CD68 staining in a tumor core biopsy after FMX dosing. (A, B) Serial tumor sections from formalin-fixed, paraffin-embedded biopsies of liver lesions were stained for (A) FMX (Prussian blue) and (B) macrophages …
View article: Figure S4 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S4 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Additional Prussian blue and CD68 staining in a tumor core biopsy after FMX dosing. (A, B) Serial tumor sections from formalin-fixed, paraffin-embedded biopsies of liver lesions were stained for (A) FMX (Prussian blue) and (B) macrophages …
View article: Supplemental Information from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Supplemental Information from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Includes additional detail concerning methods
View article: Figure S5 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S5 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Correlation between the average irinotecan concentration of the biopsied lesion of that patient and the patient's time on treatment. Biopsy samples were obtained 72 hours after nal-IRI infusion. Time on treatment is measured from the date …
View article: Data from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Data from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Purpose: To determine whether deposition characteristics of ferumoxytol (FMX) iron nanoparticles in tumors, identified by quantitative MRI, may predict tumor lesion response to nanoliposomal irinotecan (nal-IRI).Experimental Desi…
View article: Figure S1 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S1 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Sequence of study procedures.
View article: Figure S1 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S1 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Sequence of study procedures.
View article: Supplemental Information from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Supplemental Information from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Includes additional detail concerning methods
View article: Figure S3 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S3 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Correlation between FMX 72-hour signals and binding constant. (A) Mechanistic PK model for tumor deposition of FMX driven by permeability and binding parameters; example for lesion fits for low permeability/low signal retention is shown. (…
View article: Figure S3 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S3 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Correlation between FMX 72-hour signals and binding constant. (A) Mechanistic PK model for tumor deposition of FMX driven by permeability and binding parameters; example for lesion fits for low permeability/low signal retention is shown. (…
View article: Data from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Data from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Purpose: To determine whether deposition characteristics of ferumoxytol (FMX) iron nanoparticles in tumors, identified by quantitative MRI, may predict tumor lesion response to nanoliposomal irinotecan (nal-IRI).Experimental Desi…
View article: Figure S6 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S6 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
ROC analysis of FMX lesion response. Receiver operating characteristics for lesion classification according to best lesion size reduction, either as overall lesion shrinkage or partial response criteria, had an AUC {greater than or equal t…
View article: Figure S2 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Figure S2 from Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Open
Example patient (patient 009) with widespread hepatic metastasis who demonstrated a treatment response following therapy. (A) Selected axial images from FMX-MRI acquired from the FSPGR Fat-Sat breath-hold images (TE = 13.2 milliseconds). T…
View article: Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data
Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data Open
Background Methods for screening agents earlier in development and strategies for conducting smaller randomized controlled trials (RCTs) are needed. Methods We retrospectively applied a tumor growth model to estimate the rates of growth of…
View article: Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib Open
Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessar…
View article: Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions
Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions Open
View article: An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma
An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma Open
Metformin +/- rapamycin maintenance for mPDA was well-tolerated and several patients achieved stable disease associated with exceptionally long survival. Further prospective studies are needed to clarify the role of these agents in the mai…
View article: Additional file 2 of Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions
Additional file 2 of Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions Open
Additional file 2. This file contains Supplementary Table S2 which lists the top 20 signature genes for each cell type identified from scRNA-seq.